Latest LIBERTY data confirm efficacy up to 64 weeks

An updated analysis of the open label extension (OLE) of the LIBERTY trial in patients with episodic migraine who failed on two to four previous preventive therapies has confirmed the sustained efficacy of erenumab up to 64 weeks.

Read more »

Fremanezumab data confirm 12 month efficacy in patients converting from chronic to episodic migraine

A post-hoc analysis of data from a long-term safety study of patients who converted from chronic to episodic migraine with quarterly and monthly fremanezumab has confirmed continuing improvements in headache and migraine parameters at six and 12 months, with safety data in line with previous results and no discontinuations due to adverse events.

Read more »

FOCUS data show beneficial effects on migraine days and responder rates with fremanezumab in episodic and chronic migraine

New data from the Phase 3b FOCUS trial have demonstrated the efficacy of quarterly and monthly fremanezumab treatment in patients with episodic and chronic migraine who had inadequate responses to two to four previous preventive therapies.

Read more »

Benefits of galcanezumab and erenumab in chronic migraine continue after treatment cessation

Headache in patients with chronic migraine treated with galcanezumab or erenumab did not return to baseline levels within 16 weeks after termination of preventive therapy, according to data from a study carried out by Dr Uwe Reuter and colleagues at the University of Berlin, Germany. Monthly migraine days remained significantly lower than baseline, with a trend to increase over time.

Read more »